DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* VIVALIS *


 

1999 - Bretagne
Nantes
www.vivalis.com

 

Design, Manufacture
(also, Discovery, Immunology)
Key words: Vaccines, Flu, Viral diseases, EBx Cell line, Therapeutic protein, Cell Culture, EB66
Mission: to provide innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins, and to develop own vaccines and drugs in order to prevent and treat viral diseases (also deeply involved in veterinarian vaccines)
Clients: Pharmaceutical industry (own development up to clinical trials)
info@vivalis.com

Age: 18 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Grimaud (Franck) [co-founder, born 1966, MBA]
Sc.Dir.-CSO: Mehtali (Majid) [Ph.D., ex-Deltagen, Transgene, Rhône Mérieux]
Fin.Dir.-CFO: Rousseau (Philippe) [HEC, ex-Exonhit, Valigen, Genset, Mars, Paribas]
BusDev: Miniou (Pierre) [Ph.D., ex-Pierre Fabre, Transgene]
Financers (Hist.): Grimaud-La Corbière Group, Public
Note : company legal domiciliation : Roussay (49)

Turnover (M€) : 0.7 (2009), 2.5 (2008)
Total funding (M€) : 39.5
Last funding (M€) : 29.0
Focus : Multiple
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .12 Acquisition of Intercell (Austria), by merger with name change of new company as Valneva ACQ+ [13 years]
2011 .07 Partnering commercial agreement with Transgene, on EB66 cell line for the manufacturing of Transgene MVA-based therapeutic vaccines MKTG [12 years]
2010 .09 Partnering research agreement with Mymetics (Switzerland), to evaluate the replication of an undisclosed virus in EB66 cell line for the manufacturing of human vaccines R&D [11 years]
2010 .07 Round financing : 30.0 M€ through capital increase from Grimaud (15.5 M€), indirectly derived from FSI grant RFIN [11 years]
2010 .06 R&D : new laboratory unit with a new building (3300 square meters), near Nantes INDUS [11 years]
2010 .01 Acquisition of Humalys, a private French biotech R&D company, based in Lyon, specialised in the generation of human monoclonal anti-bodies ACQ+ [10 years]
2009 .01 Partnering research agreement with Innate Pharma to produce IPH 4101 with EB66 for clinical trials (Oseo debt financing grant of 3.0 M€ for Vivalis) R&D [9 years]
2008 .10 Licensing-out of EB66 cell line to CSL to test for the development and manufacturing of a therapeutic protein candidate LICOUT [9 years]
2007 .06 Listing on Euronext : 29.0 M€ PBO [8 years]
2005 .00 Production : new manufacturing unit with a new building (1500 square meters), near Nantes INDUS [5 years]
2004 .11 2nd round-financing : 5.3 M€, by Grimaud Group, FCJE (CDC), Créagro, Pays de la Loire Développement, and banks, to finance the buiding of a manufacturing unit RFINB [5 years]
2003 .00 Partnering development with undisclosed company on Ebx cells R&D [3 years]
1999 .06 1st round-financing : 4.6 M€, by Grimaud Group RFINA [0 year]
1999 .04 Company founded by Grimaud Group (Franck Grimaud), based on research know-how by Dr Bertrand Pain and Dr Jacques Samarut ORGF [0 year]

Actualisation / Updating: 27-Dec-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende